BHCM
TCRX icon

Brevan Howard Capital Management’s TScan Therapeutics TCRX Stock Holding History

Brevan Howard Capital Management’s Portfolio TCRX Stock Details TCRX Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2024
Q2 		– Sell
-34,578
Closed -$275K – 1389
2024
Q1 		$275K Buy
+34,578
New +$218K ﹤0.01% 690

Other funds holding TCRX

LCM
Lynx1 Capital Management San Juan, Puerto Rico $633M AUM 173.22% 1-Year Est. Return
EC
EcoR1 Capital San Francisco, California $2.36B AUM 204.53% 1-Year Est. Return
BlackRock
BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return
Adage Capital Partners
Adage Capital Partners Boston, Massachusetts $64.8B AUM 42.7% 1-Year Est. Return
BI
BVF Inc San Francisco, California $3.14B AUM 249.53% 1-Year Est. Return
BBA
Baker Bros. Advisors New York $17.4B AUM 131.5% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
PBM
Propel Bio Management Los Angeles, California $159M AUM 60.94% 1-Year Est. Return
DMC
Deer Management Company Larchmont, New York $622M AUM 24.27% 1-Year Est. Return
AI
Alphabet Inc Mountain View, California $4.02B AUM 215.74% 1-Year Est. Return

Brevan Howard Capital Management's TCRX Position: Q2 2024 in Review

Brevan Howard Capital Management sold out of TScan Therapeutics (TCRX) in Q2 2024, closing a stake of 34,578 shares — an estimated $275K sold.

Brevan Howard Capital Management first reported a position in TCRX in Q1 2024 and held it in 1 quarter. The position peaked at $275K in Q1 2024. 80 funds tracked by Wall St. Rank hold TCRX as of Q2 2024.

  • Brevan Howard Capital Management reported no remaining TScan Therapeutics position as of Q2 2024 after selling out during the quarter.
  • Brevan Howard Capital Management sold 34,578 TScan Therapeutics shares in Q2 2024, an estimated $275K.
  • Brevan Howard Capital Management first reported a position in TScan Therapeutics in Q1 2024 and held it in 1 quarter.
  • Brevan Howard Capital Management's TScan Therapeutics position peaked at $275K in Q1 2024.
  • 80 funds tracked by Wall St. Rank held TScan Therapeutics as of Q2 2024.

Based on Brevan Howard Capital Management's 13F filing for Q2 2024, filed 14 Aug 2024.